Monday, February 5, 2018

No change to pack sizes

Australian Journal of Pharmacy (blog)-15 hours ago
This proposal sought to create a new S3 entry for orphenadrine in “oral preparations containing 35 mg or less of orphenadrine when compounded with not more than ... occurrence of abuse episodes, OD-induced deaths, adverse cardiac events, drug-druginteractions, and incompatible pharmacokinetics with other drugs.
Post a Comment